Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14693MR)

This product GTTS-WQ14693MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in B cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14693MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1328MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ4569MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9837MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ13099MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ14410MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ6486MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ3062MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW